Use of Fludarabine-Containing Chemotherapeutic Regimen Results in Durable Complete Remission of Subcutaneous Panniculitis-Like T-Cell Lymphoma

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare lymphoma. The optimal therapy for SPTCL is undefined and the results of treatment with anthracycline-containing chemotherapy for aggressive cases have remained poor. A 27-year-old woman with multifocal and aggressive CD8+ SPTCL was tre...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2008-01, Vol.9 (6), p.396-398
Main Authors: Chim, Chor-Sang, Loong, Florence, Ng, Wai-Kuen, Kwong, Yok-Lam
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Care and treatment
Case Report
Case studies
Dermatology
Dexamethasone - administration & dosage
Diagnosis
Drug therapy
Female
Fludarabine
Health aspects
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, T-Cell - drug therapy
Lymphoma, T-Cell - pathology
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mitoxantrone - administration & dosage
Panniculitis - pathology
Pharmacology/Toxicology
Pharmacotherapy
Skin involvement in other diseases. Miscellaneous. General aspects
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
T cell lymphoma
Vidarabine - administration & dosage
Vidarabine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare lymphoma. The optimal therapy for SPTCL is undefined and the results of treatment with anthracycline-containing chemotherapy for aggressive cases have remained poor. A 27-year-old woman with multifocal and aggressive CD8+ SPTCL was treated with the purine analog fludarabine in combination with mitoxantrone and dexamethasone (FND). The patient achieved complete remission after one course of treatment. After completion of six courses of FND, the patient has remained in remission for more than 3 years. FND may be an effective treatment for aggressive SPTCL.
ISSN:1175-0561
1179-1888
DOI:10.2165/0128071-200809060-00007